High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche's diagnostics division, allowing the company to raise its sales forecast for the year.
Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage cases that can be
Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should
NICE has recommended routine NHS access to Roche's cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (C
Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing its benefits when given to pre-symptomatic babies with the rare disease.